Efficacy of PosBion® Postbiotic Supplementation in Adults With Irritable Bowel Syndrome
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- My Myracle Sdn.Bhd
- Trial code
- NCT07699926
- Record updated
- 14 July 2026
- Original description
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by recurrent abdominal pain and altered bowel habits, often associated with impaired intestinal barrier function, low-grade inflammation, and dysregulation of the gut-brain axis. Postbiotics have emerged as a promising therapeutic approach due to their immunomodulatory, anti-inflammatory, and gut barrier-protective properties.Read full original descriptionShow less
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by recurrent abdominal pain and altered bowel habits, often associated with impaired intestinal barrier function, low-grade inflammation, and dysregulation of the gut-brain axis. Postbiotics have emerged as a promising therapeutic approach due to their immunomodulatory, anti-inflammatory, and gut barrier-protective properties.
This completed single-arm, open-label clinical study evaluated the efficacy of PosBion® postbiotic supplementation in adults with IBS over a 12-week intervention period. The study assessed changes in IBS symptom severity, quality of life, gastrointestinal health, inflammatory biomarkers, intestinal barrier integrity, mucosal immunity, oxidative stress, and gut-brain axis biomarkers using validated questionnaires and salivary biomarker analyses.
Inclusion: Experienced one or more symptoms consistent with irritable bowel syndrome (IBS), including:; Stomach pain or abdominal cramps; Bloating; Excessive gas; Diarrhoea; Constipation (or alternating diarrhoea and constipation); Mucus in stool; Urgency to defecate; Sensation of incomplete bowel evacuation; Willing and able to comply with all study procedures and scheduled visits; Provided written informed consent before study participation.
Exclusion: Current use of antibiotics or antiviral medications; Major surgery within the previous 6 months; Known allergy or hypersensitivity to any ingredient of the investigational product; History of chronic or serious medical conditions, including but not limited to diabetes mellitus, cardiovascular disease, chronic kidney disease, cancer, or chronic respiratory disease; Any condition that, in the opinion of the investigators, could interfere with study participation, compliance, or interpretation of the study results; Current use of supplements intended to improve gut health; Current use of probiotic, prebiotic, or postbiotic supplements; Pregnant or breastfeeding women.